Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

Electronic Proceedings for 10th US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA

 

Curator: Aviva Lev-Ari, PhD, RN

 

LIVE — 9AM-noon US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA

https://pharmaceuticalintelligence.com/2016/06/02/live-9am-noon-us-india-biopharma-healthcare-summit-june-2-2016-marriott-cambridge-ma/

 

LIVE 11:45AM – 2:40PM US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA

https://pharmaceuticalintelligence.com/2016/06/02/1145am-240pm-us-india-biopharma-healthcare-summit-june-2-2016-marriott-cambridge-ma/

 

LIVE 3:15PM – 5:00PM US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA

https://pharmaceuticalintelligence.com/2016/06/02/315pm-500pm-us-india-biopharma-healthcare-summit-june-2-2016-marriott-cambridge-ma/

 

 

 

Read Full Post »

LIVE 3:15PM – 5:00PM US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN

 

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

will cover in Real Time using Social Media the

10th US-India BioPharma & Healthcare Summit,

June 2, 2016

Aviva Lev-Ari, PhD, RN will be streaming LIVE from the 

Marriott Cambridge, MA

@USAIC

#USAIC16

@pharma_BI

@AVIVA1950

SPEAKERS

http://usaindiachamber.org/current-events.shtml

3-15 PM – 4-05 PM Panel Discussion: Cardiovascular and Metabolic Diseases- Matters of the heart and the body

Moderator:
Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.

  • What are the trends
  • Hoe Genomics affects
  • Effect behavior by data from Devices like FitBit
  • Gene Editing
  • COllaboration potential with India

Panelists:

  • Neil McDonnell, PharmD, Chief Executive Officer, Metacrine
  • Dr. Anthony Muslin, Vice President, Head of the Cardiovascular & Fibrosis Unit, Sanofi
          1. Area of study: insulin sensitizers
          2. NASH — effects of insulin sensitizers on
          3. CVD — effects of insulin sensitizers on
          4. CNS — effects of insulin sensitizers on
          5. Genomic in Metabolic: Blocking hormone
          6. Two drugs that showed effect on CVD
          7. Antidiabetics inn NASH
          8. Diabetes and Renal
          9. Collaboration with India: VC, Pharma, Seizened Management Teams
  • Dr. Robert Plenge, VP and Head of Translational Medicine, Merck Research Labs
  1. Cholesterol – gene editing vs drug for the mutation
  2. Data analytics of big data — build Teams with al capabilities
  • Dr. Arthur Tzianabos, President & CEO, Homology Medicines
  1. Genomics and Genetics – few have been studied yet,
  2. genes to be targeted for editing
  3. In CVD – Gene Editing – cure disease at the origin: repair the gene transcription
  4. Ittalia, Editas
  5. In vivo genetics: Viruses and nanoparticles
  • Dr. Murali Vemula, Founder & President, Nivarta
  1. CVD
  2. Small molecule

Questions from the Floor

  • Burden of disease is high in India and CHina, Lovostatin, Metformin, Anti-Hypertensive — Decrease the burden og the disease
  • India has capabilities in IT — Harness that to Genomics?
4-05 PM – 4-55 PM Panel Discussion: Regulatory Policies to foster R&D Innovation

Moderator:
Dr. William Chin, Executive Vice President, PhRMA

  1. Regulatory – Roadblock and barriers
  2. Regulatory – Catalist
  3. This is a Bias: Partners with Academia, Industry Cell therapy, CRISPR
  4. Biomarkers – Approval by Regulator is not forthcoming

Panelists:

  • Dr. Ariz Ahammed IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India
  • Dr. Christopher Corsico, Chief Medical Officer, Boehringer Ingelheim GmbH
  1. If benefit is clear – Regulatory will act fast to accelerate
  2. Gov’t vs Regulators that are TOO much partnering with Companies applying for approval
  • Rajiv Kaul, Portfolio Manager, Fidelity Investments
  1. Intellectual Capital from all over the WOrld arrive to Cambridge
  2. Gov’t and industry to come together otherwise the Cost of Capital is too high
  3. Regulatory is necessary for Public Safety
  4. Regulatory is a barrier if a company stock depends 100% on Approval  – Colatico – approved in 3 Month
  5. Speed is important to Patients and to investors and to Patients
  6. New classification Noval Inventions: Fast approval – investors like this class of drugs
  • K.L. Sharma, IAS, Joint Secretary, Ministry of Health & Family Welfare, Govt. of India
  1. Public Health is of concern
  2. safety and efficacy is of great importance
  3. sociopolitical factors affect various States in India – Harmonization need be accomplished across States
  • Dr. Tsutomu Une, Corporate Advisor, Daiichi Sankyo Co., Ltd.
  1. Understanding he Patient and the family
  2. Priorities for patints vs Industry selfishness

Questions from the Floor

  1. Drug – device not fast approve – WHAT need to be done to accelerate this process
  2. Exploratory Development Submission —  New Scientific Concept  – concept and the Science behind and value – educate the Regulator – harmonize among regulatory agencies
  3. Concept presenented to Investors EARLY before we have the data
4-55 PM – 5-25 PM Participants comments
5-25 PM – 5-30 PM Closing Remarks

Read Full Post »

LIVE 11:45AM – 2:40PM US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN

 

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

will cover in Real Time using Social Media the

10th US-India BioPharma & Healthcare Summit,

June 2, 2016

Aviva Lev-Ari, PhD, RN will be streaming LIVE from the 

Marriott Cambridge, MA

@USAIC

#USAIC16

@pharma_BI

@AVIVA1950

 

SPEAKERS

http://usaindiachamber.org/current-events.shtml

11-45 AM – 12-35 PM Panel Discussion: Drug Discovery and Collaborative Research: The path forward

Moderator:
Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

  • Opportunities for collaborations with india

Panelists:

  • Dr. Ariz Ahammed IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India
  1. Silos in the indian Government are high and a need to communicate and collaborate is much needed
  2. collaborations 4 took place past year
  3. Institutional Collaboration requires investment in Scientists
  4. Academics focus on publications, in Pharmaceuticals – deliverables are different that publications
  • Dr. Barry Bloom, Distinguished Service Professor, Harvard School of Public Health
  1. Interest is high in the US f fro Partnerships with global players
  2. India 1.2% of GDP is spent on Health in the US 17.4%
  3. In India Great Research Centers NOT connected to Hospitals or Industry
  4. Partnerships need be developed first in side India
  5. Public Health in India: Public Sector vs Private Sector for Infectious diseases
  6. Would like to see Global needs that India has advantages, monopoly on infection diseases in India, investment in anti-microbial declined in the US to minimum, India can make great contributions in anti-microbial
  7. What are the incentives to pursue collaborations?
  8. The government must play a role in India like NIH, NSF, CDC in the US
  • Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences
  1. Problems in need to be solved are different not all can be in-house, reaching out to people and seeking technologing and relationships
  2. Networks not Silos as in the 80s, in 2016 behaviors and business model and sharing of information – advantages for new uses to same patents
  3. In the manhattan Projects a lot was accomplished across institutions and understand the interdependencies vs optimizing own’s environment
  4. people management with well defined interactions and relationships and roles
  5. convergence of Science Innovations, India has the potential to become at the top of the Scientific Community, there are Centers that demonstrates outstanding success
  • Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals
  1. Value of Partnerships as fundamental to business is today more the case then in the near Past
  2. Partnership increase is a function of Internal R&D Costs that are too high
  3. What models work? Relationship with a Partner – Mindset of being agile, both parties need to win, synergi=y needs be accomplished, small company to commercialize – Partnerships vs Exit is the strategy at Present
  4. Investments in NYC, Munich, Singapose, in the US: SF, Boston, SanDiego, UK: Cambridge
  5. Hospitals in India for 2.1 Billion
  • Anil Raghavan, Chief Executive Officer, Sun Pharma Advanced Research Company
  1. Ideas can come from all over the world, US: Boston, San Francisco where the competition is high
  2. the tradisional structure of institutions need to change to allow for collaborations – protection of each institution

 

Questions from the Floor:

  • Patients participate in Clinical Studies

 

12-35 PM – 1-05 PM Fireside Chat with Dr Griffin Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health

Moderator:
Dr. William Chin, Executive Vice President, PhRMA

  • What diagnostics can be developed for the HealthCare Market in India
  • Translational Research and basic research — WHich is more importnat – Dr. CHin: Translational

Dr Griffin Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health

  • One of 27 Institutes of the NIH
  • 85% of budget supports Scientists OUTSIDE the NIH
  • Collaborative research over $1Billion NIH invested in Diabetes
  • National Diabetes Federation highlights that in the US, India, China – will have same number of patients affected by Diabetes
  • 2012  Joint agreement for collaboration
  • Research Trends in Diabetes: Resistence in DM2
  • Partnership: Academia, Medical Partnerships to discovery new therapeutics for DM2, other initiatives: Autoimmune, CVD – Data sharing: Academics and Industry, NIH research and Hospitals 
  • to 2019 – when all data will be all accessible by American Diabetes Association
  • Receptors and co-activations, Kinases, ion-channels
  • Agreement in 2013 to develop: DM-HIV-TB collaboration with india.
  • DM@ Patients have an increase infectivity for HIV and TB !!
  • Glacemia monitoring statins controlling lipids, cost effective treatment
  • Kidney disease is a complecation of Diabetes: DM1 it is possible to control kidney disease by drugs
1-05 PM – 2-40 PM Luncheon Panel Discussion: Oncology- Immuno-oncology, data analytics and value platforms – the new world order

Moderator:
Colin Hill, Chairman & CEO, GNS Healthcare

  1. Chemo therapy still is the backbone – this is changing
  2. success of monoclonal antibodies
  3. Target therapy
  4. Patient selection strategy — will speed drug development and cost effectiveness will increase
  5. cost containment by Payers
  6. uptake of Biomarker research to perfect them
  7. embed Biomarket with the drug, or with the therapy lab work
  • top 3 transformations in ImmunoOncology, CRISPR, Value-Outcome

Panelists:

  • Dr. Bruce Chabner, Director of Clinical Research, MGH Cancer Center
  1. FDA – Biomarkers need be developed
  2. Understanding Drug resistance
  • Dr. Arun Chandavarkar, CEO & Joint Managing Director, Biocon
  1. Value
  2. Drug affordability
  • Dr. Gordon Freeman, Professor of Medicine, Dana-Farber Cancer Institute/HMC
  1. PDL1 – expresses in vivo on tumor surface
  2. tumon turn off immune response
  3. combination with the Foundation therapy PDL-1
  4. reeducation of oncologist on adverse effects that are differennt from these of CHemo
  5. Multiple PDL1 actors, BioSimilars small molecules will emerge to mimic the effect
  6. PDL1 – can be a commodiyt for many more Patients
  7. 10% adverse effects of immune systems for PDL1
  8. 70% correlation of Biomarker and drugs – not like precision gene testing
  9. clonal viral: Viral diseases – low cost PD! possibility for underdeveloed countries
  • Dr. Sandeep Gupta, President & CEO, Asana BioSciences
  1. Combination
  2. time to success is too long
  • Dr. Rakesh Jain, Director, E.L. Steele Laboratory of Tumor Biology, MGH Cancer Center
  1. checkpoint are effective
  • Dr. Daniel Omstead, President & CEO, Tekla Capital Management
  1. Combination drug therapy – how the reimbursements
  2. Regulatory and reimbursement – adaptive clinical trial design, diagnostics
  3. Novel vs small follow ups

 

Read Full Post »

LIVE — 9AM-noon US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

will cover in Real Time using Social Media the

10th US-India BioPharma & Healthcare Summit,

June 2, 2016

Aviva Lev-Ari, PhD, RN will be streaming LIVE from the

Marriott Cambridge, MA

 

@USAIC

#USAIC2016

@pharma_BI

@AVIVA1950

SPEAKERS

http://usaindiachamber.org/current-events.shtml

9-15 AM – 9-30 AM Welcome address by Karun Rishi, President, USA-India Chamber of Commerce

Progress made in last two years, we need faster advancement. Thanks to all attendees and those who came for far away.

Opening comments
by Master of Ceremonies – Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

Biomedical field, important issues are covered today. Karun is a Force of Nature. Guests from India, welcome.

Innovation in BioTech and understanding Disease is exploding

  • Ability to attack disease is amazing
  • Pipelines synthetic, small molecule – THE Past — today new unconventional therapies

India’s role:

  • Innovation space in India – diversification in modalities
  • Partnerships
  • # of Rounds in Financing: 67 new start ups in 2015 in the US – Academic Start Ups
  • Models in India: we need to figure out which types will work best in India

Takeda and Japan

  • Strong academic science
  • rich history of productivity in R&D
  • Commercialization of R&D is not strong in Japan
  • Institute outside of Tokyo: Academia and Industry collaboration
9-30 AM – 9-55 AM India Regulatory and Clinical Research Update
K.L. Sharma, IAS, Joint Secretary, Ministry of Health and Family Welfare, Government of India

  • Ministry of Health and Family Welfare is keen to improve and progress
  • Federal funds will be distributed to 60 States for Reform, Actions
  • Good Laboratories Practices, Manufacturing Practices Processes, CMP, GMP,
  • Risk assessment based on data from Manufacturing and inspection
  • Regulatory aspects and validation – largest in the World quality effort of manufacturing, August 2016 – results will be sahred
  • Medical Devices: ISO – extensive cooperation to amend the Law and add New Lawsto provide compeling reason for rules and standards in Medical Devices and Prostesis
  • Biologics, Stem Cells
  • Collaboration between Medical Institutions, Academic Institution
  • Recruiting from industry to the Government
  • Toxicology studies
  • Acredidation process
  • Put in Public Domain: Information on products, all new regulation
  • International hamonization

Questions from the Podium

    • Academia: Collaboration
    • J-J: IF the doors are open – How we can connect to develop relations
    • How International hamonization can take place with each of the States
  • Committes from Laboratories, Central Govenrment and Industry
    • US -India collaborations: Improvements on the way
9-55 AM – 10-45 AM Panel Discussion: Neurodegenerative diseases – Matters of the mind

Moderator:
Dr. Ole Isacson, Professor of Neurology, Harvard Medical School

The most difficult field in Medicine, opportunities in Academia and in Industry — in last ten years these two groups merged in interest to solve the problem, Genetics work with Neuro to develop drugs, pathology and Neurologist discussions associations with immunology and oncology

  • 5 Millions in the US affected by Neurological Diseases
  • Role of Stem Cells
  • gene therapies

Panelists:

  • 5 – Dr. John Dunlop, Vice President & Head, Neuroscience, AstraZeneca
  1. Clinical Studies  – data on antibodies need to be sahred AZ invested in Amyloid Hypothesis
  2. ALS, MS, Parkinson
  • 3 – Dr. Douglas Feltner
  1. Antibodies made  – cause fight with inflammation
  2. MS, Parkinson, AZ – very complex diseases
  3. Longitudinal changes,
  • 4 – Philippe Lopes-Fernandes, Senior Vice-President, Merck KGaA

Adherence with medicine and treatment cause of 15 years

  • 2 – Dr. Alfred Sandrock, Executive Vice President and Chief Medical Officer, Biogen

DO belief in Beta-Amyloid hypothesis is causal hypothesis, In early patients – reduction of plaque by the drug very quickly, Early CLinical Trial, progression monitoring, TAU present and spread beyond temporal lobe, microglial cells can be protected, helpful to preserve neurons,

  1. Need to understand Pathways,
  2. know how to mitigate risk along the way, reduce risk of investment in a disease solution may not come by instead of investment on a drug for a disease curalble NEURO is more difficult
  3. How Indian Scientists can particiapte
  4. even with inheretance, protected by other factors
  5. Intracellular proteins
  • 1 – Dr. Rudolph Tanzi, Director, Genetics and Aging Research Unit, Mass General Hospital

Biology of Alzheimer’s Disease: Loss of synapses, 4 genes, Amyloid Hypothesis – debatable, head-concussions, genes for inflammation, Human models, C1-2, diet, Statin, APO-4 E2, E3 – lipid componenet – role in amyloid transport

  1. Cross -pathologies disease specifics
  2. mutations that protect us, plaque is present NO Ad, resilience
  3. Brain-Microbiome: Infections in th eBrain

Questions from the Floor

  • Etiology
  • Biomarkers
10-45 AM – 11-15 AM Fireside Chat with

  • Dr David Meeker, Head, Sanofi Genzyme

 

  1. How we build value
  2. specialty care business  – systemic growth
  3. Where is the probability the highest?
  4. Pay to Play – a start not an end game
  5. R&D effert internally must be very strong before acquision are to take place
  6. ecosystem is critically important
  7. Resource allocations remains important in strategy

 

  • Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries Limited – India based

 

  1. How innovations in India can impact positively the Cost of HealthCare
  2. 4 products at different stages
  3. Partnerships wiht International companies are needed in areas the expertise is not enough
  4. 50% of products are for international markets
  5. consistency and scalability
  6. Partnerships with Biotech are important for growth – joint value for bigger position
  7. In our strategy I am Seeking
  • partner in oncology,
  • other drugs to use out technology for drug delivery,
  • excaplulate our expertise in exosome lipidsome for other targets
  • Proof of Concept transfer to products the process id lengthy
  • BioSimilar – BioPharma — important sector for Pharma
  • Fear of failure

Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Read Full Post »

10th US-India BioPharma & Healthcare Summit, Thursday, June 2, 2016, Marriott Cambridge, MA

Guest Reporter of this Event on @pharmaceuticalintelligence.com:

Karun Rishi

President

USA-India Chamber of Commerce

Tel: 781 586-1212

Twitter @ USAIC handle for the Summit #USAIC16

REGISTRATION Online

https://s01.123signup.com/servlet/SignUpMember?PG=1529661182300&P=15296611911420195500

About Us Structure Current Events Past Events Councils Policy & Reports Photo Gallery Awards Membership Media Coverage Internship/Volunteers Legal Contact Us     The USA-India Chamber of Commerce mission is to provide a pro-active & professional platform for high ranking policy makers, senior business executives, academicians, and investors in the United States and India to network, facilitate and promote trade, investments & economic cooperation. USAIC’s four point agenda is: Trade, Investment, Policy and Advocacy.   Search   10th US-India BioPharma & Healthcare Summit, Thursday, June 2, 2016, Marriott Cambridge

SOURCE

http://usaindiachamber.org/current-events.shtml

 

SPEAKERS

http://usaindiachamber.org/current-events.shtml

AGENDA

Master of Ceremonies (Emcee)– Andrew Plump, MD, PhD; Chief Medical & Scientific Officer, Takeda Pharmaceuticals

US-India BioPharma & Healthcare Summit
Date: Thursday, June 2, 2016
Location: Grand Ballroom, Marriott Cambridge, Massachusetts, USA

* Speakers and Timings subject to change

Time Topic
8-45 AM – 9-15 AM Registration and Networking
9-15 AM – 9-20 AM Welcome address by Karun Rishi, President, USA-India Chamber of Commerce
9-20 AM – 9-30 AM Opening comments by Master of Ceremonies – Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals
9-30 AM – 10-00 AM India Regulatory and Clinical Research Update*
K.L. Sharma, IAS, Joint Secretary, Ministry of Health and Family Welfare, India
Dr G. N. Singh, Drug Controller General of India, Central Drugs Standard Control Organization
10-00 AM – 10-50 AM Panel Discussion: Neurodegenerative diseases- Matters of the mind
10-50 AM – 11-20 AM Fireside Chat with Dr David Meeker, Head, Sanofi Genzyme and Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries moderated by Dr Martin Mackay, Executive Vice President, Global Head of Research and Development, Alexion
11-20 AM -11-50 AM Networking & Tea Break
11-50 AM – 12-40 PM Panel Discussion: Drug Discovery and Collaborative Research: The path forward
12-40 PM – 1-10 PM Fireside Chat with Dr Griffin Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH moderated by Dr William Chin, Executive Vice President, PhRMA
1-10 PM – 2-40 PM Luncheon Panel Discussion: Oncology- Immuno-oncology, data analytics and value platforms – the new world order
2-40 PM – 3-15 PM Networking & Tea Break
3-15 PM – 4-05 PM Panel Discussion: Cardiovascular and Metabolic Diseases- Matters of the heart and the body
4-05 PM – 4-55 PM Panel Discussion: Regulatory Policies to foster R&D Innovation
4-55 PM – 5-00 PM Closing Remarks
5-00 PM – 6-30 PM Cocktails & Networking Reception

SOURCE

http://usaindiachamber.org/current-events.shtml

Read Full Post »

The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

MIT Media Lab
Building E14
75 Amherst Street

(Corner of Ames and Amherst)
Cambridge, MA 02139

Conference Location: Entire 6th floor of Building E14

EmTech MIT Brings The Award-Winning Journalism of MIT Technology Review To Life

The 16th annual EmTech MIT gathers preeminent thought leaders, researchers and business leaders to examine the most significant themes in emerging technologies, including:

– Rethinking Energy

– Virtual Reality, Augmented Life

– Artificial intelligence

– Global Connectivity

– Engineering a Healthy Planet

– Spotlight talks on the 10 Breakthrough Technologies

– Celebration of the 2016 Innovators Under 35

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

pharma_bi-background0238

will cover in REAL TIME

The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

http://events.technologyreview.com/emtech/16/

In attendance, streaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

@pharma_BI

@AVIVA1950

 All Speakers

SOURCE

http://events.technologyreview.com/emtech/16/#section-about

Featured Speakers

 

  • Nora
    Ayanian

    Gabilan Assistant Professor, University of Southern California

    2016 Innovator Under 35

  • Amir
    Banifatemi

    Prize Lead, X Prize

    Incentivizing Innovative Approaches & Collaboration in A.I.

  • Muyinatu
    Bell

    Assistant Professor, Johns Hopkins University

    2016 Innovator Under 35

  • Brian
    Bergstein

    Executive Editor, MIT Technology Review

  • Nessan
    Bermingham

    Chief Executive Officer, President and Founder, Intellia Therapeutics

    The Potential for Genome Editing Technology to Transform Medicine

  • Dinesh
    Bharadia

    Postdoctoral Associate, MIT CSAIL

    2016 Innovator Under 35

  • Heather
    Bowerman

    CEO & Founder, Dot Laboratories

    2016 Innovator Under 35

  • Elizabeth
    Bramson-Boudreau

    Chief Operating Officer, MIT Technology Review

  • Qing
    Cao

    Research Staff Member, IBM T.J. Watson Research Center

    2016 Innovator Under 35

  • Jagdish
    Chaturvedi

    Director, Clinical Innovations, InnAccel

    2016 Innovator Under 35

  • David
    Cox

    Assistant Professor of Molecular and Cellular Biology and of Computer Science, Harvard University

    Building Computer Vision Systems Inspired by the Brain

  • Tom
    Davenport

    President’s Distinguished Professor of Information Technology & Management, Babson College

    Presented by RAGE Frameworks

  • Stefano
    Domenicali

    CEO, Automobili Lamborghini

    Presented by the Italian Trade Agency

  • Kevin
    Esvelt

    Assistant Professor, MIT Media Lab

    The Technology Driving Gene Drives

  • Vivian
    Ferry

    Assistant Professor, University of Minnesota

    2016 Innovator Under 35

  • Wei
    Gao

    Postdoctoral Fellow, University of California, Berkeley

    2016 Innovator Under 35

  • Dileep
    George

    Cofounder, Vicarious

    Artificial Intelligence At Work

  • Shyam
    Gollakota

    Assistant Professor, University of Washington

    10 Breakthrough Technologies of 2016: Power from the Air

  • Meron
    Gribetz

    CEO, Meta

    2016 Innovator Under 35

  • Jiawei
    Gu

    Cofounder, Ling Robotics

    2016 Innovator Under 35

  • Rachel
    Haot

    Managing Director, 1776

    Incubating Technical Solutions with Global Impact

  • Alex
    Hegyi

    Member of Research Staff, PARC

    2016 Innovator Under 35

  • Katherine
    High

    Cofounder, President and Chief Scientific Officer, Spark Therapeutics

    Gene Therapy: A New Era of Medicine

  • Christine
    Ho

    CEO, Imprint Energy, Inc.

    2016 Innovator Under 35

  • Ehsan
    Hoque

    Assistant Professor, University of Rochester

    2016 Innovator Under 35

  • Solomon
    Hsiang

    Chancellor’s Associate Professor of Public Policy, University of California, Berkeley

    Addressing the Effects of Climate Change

  • Karl
    Iagnemma

    CEO and Cofounder, nuTonomy

    Intelligent Machines: Autonomous Cars

  • Sangbae
    Kim

    Associate Professor of Mechanical Engineering, MIT

    Robots at Work

  • Samay
    Kohli

    Chief Executive Officer, GreyOrange

    2016 Innovator Under 35

  • Kendra
    Kuhl

    CTO, Opus 12

    2016 Innovator Under 35

  • Maithilee
    Kunda

    Assistant Professor, Vanderbilt University

    2016 Innovator Under 35

  • Stephanie
    Lampkin

    Founder & CEO, Blendoor

    2016 Innovator Under 35

  • Desmond
    Loke

    Assistant Professor, Singapore University of Technology and Design

    2016 Innovator Under 35

  • Evan
    Macosko

    Instructor, Harvard Medical School

    2016 Innovator Under 35

  • Yael
    Maguire

    Engineering Director, Facebook Connectivity Lab

    Expanding the Global Impact of Internet Connectivity

  • Vikram
    Mahidhar

    SVP, Artificial Intelligence Solutions, RAGE Frameworks

    Presented by RAGE Frameworks

  • Marcela
    Maus

    Director of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center

    The Promise of Cancer Immunotherapy

  • Pranav
    Mistry

    Global Vice President of Research, Samsung

    Envisioning What’s Next for Virtual Reality

  • Jason
    Pontin

    Editor in Chief and Publisher, MIT Technology Review

  • Ramesh
    Raskar

    Director, MIT Media Lab Camera Culture Group

    Presented by Lemelson-MIT

  • Alberto Maria
    Sacchi

    Board Member & Past President, Federmacchine

    Presented by the Italian Trade Agency

  • Don
    Sadoway

    Professor, Materials Science & Engineering, MIT

    Providing Power for a Growing Global Population

  • Ruslan
    Salakhutdinov

    Associate Professor, Carnegie Mellon University

    The Promise and Limitations of Machine Learning

  • Kelly
    Sanders

    Assistant Professor, University of Southern California

    2016 Innovator Under 35

  • Michele
    Scannavini

    President, Italian Trade Agency

    Presented by the Italian Trade Agency

  • Stefanie
    Tellex

    Assistant Professor, Computer Science, Brown University

    10 Breakthrough Technologies of 2016: Robots That Teach Each Other

  • Ronaldo
    Tenorio

    CEO, Hand Talk

    2016 Innovator Under 35

  • Sonia
    Vallabh

    PhD Student, Prion Scientist, Broad Institute

    2016 Innovator Under 35

  • Cyrus
    Vance Jr.

    Manhattan District Attorney, Manhattan District Attorney’s Office

    Security & Privacy in the Connected Era

  • Oriol
    Vinyals

    Research Scientist, Google DeepMind

    2016 Innovator Under 35

  • Aleksandra
    Vojvodic

    Assistant Professor, University of Pennsylvania

    2016 Innovator Under 35

  • Padmasree
    Warrior

    CEO, NextEV

    Imagining Clean, Connected Transportation

  • Jean
    Yang

    Assistant Professor, Carnegie Mellon University

    2016 Innovator Under 35

  • Yihui
    Zhang

    Associate Professor, Tsinghua University

    2016 Innovator Under 35

  • Jia
    Zhu

    Professor, Nanjing University

    2016 Innovator Under 35

 

Read Full Post »

Diversification and Acquisitions, 2001 – 2015: Trail known as “Google Acquisitions” – Understanding Alphabet’s Acquisitions: A Sector-By-Sector Analysis

Reporter: Aviva Lev-Ari, PhD, RN

 

GoogleAcquisitons

SOURCE

https://www.cbinsights.com/research-google-acquisitions?utm_source=CB+Insights+Newsletter&utm_campaign=2d8a0dbc59-TuesNL_05_03_2016&utm_medium=email&utm_term=0_9dc0513989-2d8a0dbc59-87377285

 

Understanding Alphabet’s Acquisitions: A Sector-By-Sector Analysis

Google has made nearly 200 acquisitions since 2001. When the company reorganized as a new entity called Alphabet in late 2015, the new structure refocused attention on Google’s non-advertising businesses, including Calico (healthcare), Google X (self-driving cars , robots, etc.), and Nest (smart home), all of which now effectively operate as their own divisions.

We analyzed some of the sectors outside search and digital advertising where Alphabet has made recent acquisitions:

MEDIA AND ENTERTAINMENT

Google paid $1.7B for YouTube in 2006 in what is widely regarded as one of the most important consumer tech acquisitions of all time. Since then, Google has acquired more video-related companies whose technologies were absorbed into YouTube, including an easy-to-use video-creation tool (Directr), video-rendering tech (Zync), and social video software (Omnisio).

More recently, YouTube has signaled its interest in content, acquiring Next New Networks in 2011 (it became YouTube’s Next Lab to scout talent) and Vidmaker (a kind of Google docs for video editing, used by semi-professional and professional video creators). The rollout of YouTube Red, an ad-free subscription-based version of YouTube, could point to more content-related acquisitions if the model succeeds.

VR is another area of interest for Google. The company acquired Skillman & Hackett, which makes software that allows users to “paint” in virtual reality environments, and also acquired the team from Thrive Audio, which specializes in “positional audio” which will be key for adding a soundtrack to immersive VR experiences. Digisfera, a company that specializes in 360-degree imaging, has use cases in Google’s mapping projects, but could also be useful since 360-degree images are also used in VR content (YouTube has already 360-degree video support for VR enthusiasts).

AUTO TECH AND NAVIGATION 

The two fields are interrelated, with Google’s market-leading maps giving the giant a good footing in the race to build autonomous vehicles. Several of Google’s acquisitions helped make Google Maps and its underlying data more robust, including companies focused on satellites (Skybox Imaging) and crowdsourced traffic data (Waze). Google also acquired Lumedyne, a company that creates microsensors, which could be used in various car parts that could help power and refine self-driving cars.

ROBOTICS 

Alphabet made more than 7 robotics acquisitions in 2013 as the company continues to make serious forays into the space including a recently filed patents for controlling large groups of robots and creating downloadable personalities. The robotics companies that were acquired develop machines for a wide set of use cases. Boston Dynamics has developed a robotic cheetah, Industrial Perception’s robots are designed to locate objects and move them in warehouse environments, and Bot & Dolly develops robots to assist in filmmaking.

SMART HOME

Google’s largest acquisition ever was for Nest in 2014 for $3.2B, and now operates as one of Alphabet’s divisions under Tony Fadell. The company has made other acquisitions to bolster its home offerings, including Dropcam for home security and Revolv, a smart home hub. While the Revolv product was discontinued, the team helped develop Google’s OnHub, a centralized Wi-Fi and Smart Home device. Alphabet also acquired Flutter, a gesture-recognition company, which would allow for new, convenient ways for consumers to control smart home devices (Project Soli is already using gesture-recognition in really interesting ways).

COMMERCE

Since 2011, Alphabet has bought more than 15 companies involved with powering commerce and small businesses. Many acquisitions helped build “Google Shopping”, which is the company’s foray into ecommerce, and “Google Express”, a gigantic logistics endeavor for product delivery. Google also bought Rangespan and Channel Intelligence, both designed to use data to help businesses sell their goods online. In the past, the company has also purchased daily deals sites (DailyDeal, The Dealmap), targeted coupons (Incentive Targeting, Zave Networks), and loyalty programs (Punchd).

GOOGLE FOR ENTERPRISE/PRODUCTIVITY

Alphabet has several productivity products aimed at least in part at enterprises, including Drive, Hangouts, and Docs. Many of the acquisitions were early (pre-2011) and helped these products come into being, including Urchin Software (acquired in 2005), which became Google Analytics, and Writely (acquired in 2006), which fed into documents. Virtual assistants like Google Now might be enhanced through the recent acquisitions of Timeful (artificial intelligence) and Emu (natural language processing), technologies that could help create smart scheduling features. Alphabet could also be trying to enter the mobile enterprise market with the acquisition of Divide, a company that allows employees to carry a single phone with a “work” mode and “personal” mode.

CLOUD

Google has also made acquisitions to bolster its Google Cloud Platform and help it compete effectively for users and app deployments with Amazon’s AWS Microsoft’s Azure, and other providers. In 2014, Google made 4 acquisitions on this front in the form of Stackdriver, Appurify, Zync Render, and Firebase.

HEALTHCARE

While Google is heavily involved in healthcare through Google X, Calico, and its Life Sciences division, the company has made few disclosed healthcare acquisitions. The most recent was Lift Labs, a company that has developed a stabilizing spoon for people with neurodegenerative disorders like Parkinsons.

Healthcare is also a major investment area for the company’s venture arm, Google Ventures. They’ve invested in several different areas of healthcare, including insurance (Oscar), big data (Flatiron Health), and genomics (23andMe).

PAYMENTS

Google announced Android Pay almost directly after Apple announced Apple Pay. Google’s most notable payments acquisition was Softcard, a contactless NFC based mobile payments solution. originally a joint venture between AT&T, Verizon, and T-Mobile. In exchange, the carriers have agreed to pre-install Google payment apps on their phones. However, it’s unclear whether the platform has gained any traction.Google has also invested in other areas of fintech, including digital currency, crowdfunding, and more recently insurance.

TELECOMMUNICATIONS

Alphabet has become directly involved in cell and internet services through projects like Project Fi, Google Fiber, and Project Loon. Google also bought satellite company Skybox Imaging and high-altitude drone company Titan Aerospace. Both are acquisitions that could have possible ramifications for providing connectivity to developing countries, without the need for expensive and logistically complex submarine or terrestrial infrastructure.

SOURCE

https://www.cbinsights.com/research-google-acquisitions?utm_source=CB+Insights+Newsletter&utm_campaign=2d8a0dbc59-TuesNL_05_03_2016&utm_medium=email&utm_term=0_9dc0513989-2d8a0dbc59-87377285

Read Full Post »

To attract entrepreneurs who want to retain more control over their companies: Pillar will purchase shares of common stock in its portfolio companies, as opposed to preferred stock, the VC way

 

Reporter: Aviva Lev-Ari, PhD, RN

 

SOURCE

http://www.bizjournals.com/boston/blog/startups/2016/05/bostons-newest-investment-firm-wants-to-disrupt.html

 

After spending nearly two decades as a North Bridge investor, Jamie Goldstein  said he launched Pillar with the idea of upending the traditional venture capital structure to make the relationship between founders and investors more equitable and transparent.

To that end, Pillar will purchase shares of common stock in its portfolio companies, as opposed to preferred stock, a class of stock that is ubiquitous in startup investing. Preferred stock often includes clauses like anti-dilution rules that tend to favor venture capitalists over the businesses and entrepreneurs they’re investing in.

The Boston-based firm’s launch is part of a broader “founder-friendly” shift among investment firms to attract founders, as more entrepreneurs weigh the costs of ceding control over their companies to venture capitalists intent on making big returns.

He said Pillar aims to make first-round investments in companies in the areas of big data, machine learning, artificial intelligence, health care and information technology, with a preference toward founders who run their own businesses.

SOURCE

http://www.bizjournals.com/boston/blog/startups/2016/05/bostons-newest-investment-firm-wants-to-disrupt.html

Read Full Post »

LIVE Tweets via pharma_BI and by @AVIVA1950 — The 2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

Curator: Aviva Lev-Ari, PhD, RN

 

 

@pharma_BI ‏@Pharma_BI  8m8 minutes ago

Real Time Coverage and eProceedings of The 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal…https://lnkd.in/edtEPwb 

 

  1. @pharma_BI‏@Pharma_BI Apr 1

LIVE Remarks by Rachel Kaprielian, Tony Chat and Mike Huckman @ 2016 MassBio Annual Meeting 04/01/2016 12:45 PM Roya…https://lnkd.in/e9j7urU 

  1. @pharma_BI‏@Pharma_BI Apr 1

LIVE Remarks by Rachel Kaprielian, Tony Chat and Mike Huckman @ 2016 MassBio Annual Meeting 04/01/2016 12:45 PM… http://pharmaceuticalintelligence.com/2016/04/01/live-remarks-by-rachel-kaprielian-tony-chat-and-mike-huckman-2016-massbio-annual-meeting-04012016-1245-pm-royal-sonesta-hotel-cambridge-ma/ …

 

Plenary Session: The 2016 National Landscape, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Ro…https://lnkd.in/eETKZUg 

 

@pharma_BI ‏@Pharma_BI  Apr 1

LIVE @ Congressman Richard Neal – D-MA, Dean of MA Delegation 2016 MassBio Annual Meeting 04/01/2016 11AM Royal… http://pharmaceuticalintelligence.com/2016/04/01/live-congressman-richard-neal-d-ma-dean-of-ma-delegation-2016-massbio-annual-meeting-04012016-11am-royal-sonesta-hotel-cambridge-ma …

  1. @pharma_BI‏@Pharma_BI Apr 1

Plenary Session: Advanced Manufacturing, 2016 MassBio Annual Meeting… http://pharmaceuticalintelligence.com/2016/04/01/2-plenary-session-advanced-manufacturing-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma/ …

 

Plenary Session: Innovative Pricing Pricing Models: The Future is Now, 2016 MassBio Annual Meeting 03/31/2016 8:00 A…https://lnkd.in/eMBeGZG 

 

  1. @pharma_BI‏@Pharma_BI Apr 1

Plenary Session: Immunotherapy in Combination, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM R…https://lnkd.in/eFZti8T 

 

  1. @pharma_BI‏@Pharma_BI Apr 1

Plenary Session: Immunotherapy in Combination, 2016 MassBio Annual Meeting… http://pharmaceuticalintelligence.com/2016/04/01/plenary-session-immunotherapy-in-combination-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma/ …

  1. @pharma_BI‏@Pharma_BI Mar 31

An Evolving Paradigm of Drug Discovery – Externalization, Virtualization, De-virtualization, Contract Research & Str…https://lnkd.in/eYcjgpS 

  1. @pharma_BI‏@Pharma_BI Mar 31

 

Plenary Session: Biosimilars, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Ho…https://lnkd.in/eeQhTEV 

 

  1. @pharma_BI‏@Pharma_BI Mar 31

Plenary Session: Price & Value, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta…https://lnkd.in/e346Pz2 

  1. @pharma_BI‏@Pharma_BI Mar 31

LIVE @ Sonesta – 2016 MassBio 11:45AM – 1:30AM The MassBio Annual Award Lunchon https://lnkd.in/eGFc9F7 

  1. @pharma_BI‏@Pharma_BI  Mar 31

LIVE @ Sonesta – 2016 MassBio 11:45AM – 1:30AM The MassBio Annual Award Lunchon http://pharmaceuticalintelligence.com/2016/03/31/live-sonesta-2016-massbio-1145am-130am-the-massbio-annual-award-lunchon …

  1. @pharma_BI‏@Pharma_BI  Mar 31

Plenary Session: The Microbiome, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta…https://lnkd.in/evurHqT 

  1. @pharma_BI‏@Pharma_BI  Mar 31

2016 MassBio LIVE @ Sonesta — Welcome Remarks & Keynote – Kate Marshall @MassBio – Annual Meeting 03/31/2016 8:00 AM…https://lnkd.in/e525npG 

  1. @pharma_BI‏@Pharma_BI  Mar 31

2016 MassBio LIVE @ Sonesta — Welcome Remarks & Keynote – Kate Marshall @MassBio – Annual Meeting 03/31/2016 8:00… http://pharmaceuticalintelligence.com/2016/03/31/2016-massbio-live-sonesta-welcome-remarks-keynote-kate-marshall-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma-331-9am-10 …

@@@@

 

Aviva Lev-Ari ‏@AVIVA1950  5m5 minutes ago

Real Time Coverage and eProceedings of The 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2… http://pharmaceuticalintelligence.com/2016/04/03/real-time-coverage-and-eproceedings-of-the-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-cambridge-ma/ … via @Pharma_BI

 

Aviva Lev-Ari ‏@AVIVA1950  Apr 1

LIVE Remarks by Rachel Kaprielian, Tony Chat and Mike Huckman @ 2016 MassBio via @Pharma_BI @MassBio #AM2016 #PATIENTDRIVEN #AVIVA1950

 

Aviva Lev-Ari ‏@AVIVA1950  Apr 1

The 2016 National Landscape, 2016 MassBio Annual Meeting via @Pharma_BI @MassBio #AM2016 #PATIENTDRIVEN @AVIVA1950

 

 

 

Aviva Lev-Ari ‏@AVIVA1950  Apr 1

LIVE @ Congressman Richard Neal – D-MA, 2016 MassBio Annual Meeting 04/01/2016 via @Pharma_BI @MassBio #AM2016 #PATIENTDRIVEN @AVIVA1950

 

Aviva Lev-Ari ‏@AVIVA1950  Apr 1

Innovative Pricing Pricing Models: The Future is Now, 2016 MassBio Annual Meeting … @Pharma_BI @MassBio #AM2016 #PATIENTDRIVEN @AVIVA1950

 

Aviva Lev-Ari ‏@AVIVA1950  Apr 1

Immunotherapy in Combination, 2016 MassBio Annual Meeting via @Pharma_BI @MassBio #AM2016 #PATIENTDRIVEN@AVIVA1950

 

Aviva Lev-Ari ‏@AVIVA1950  Apr 1

Plenary Session: Immunotherapy in Combination, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/… http://pharmaceuticalintelligence.com/2016/04/01/plenary-session-immunotherapy-in-combination-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma/ … via @Pharma_BI

 

 

Aviva Lev-Ari ‏@AVIVA1950  Mar 31

Drug Discovery – Externalization, Virtualization, partnerships-2016-massbio-@Pharma_BI @MassBio #AM2016 #PATIENTDRIVEN @AVIVA1950

 

Aviva Lev-Ari ‏@AVIVA1950  Mar 31

Biosimilars, 2016 MassBio Annual Meeting 03/31/2016 cambridge-ma/ via @Pharma_BI @MassBio @AVIVA1950 #AM2016 #PATIENTDRIVRN

 

Aviva Lev-Ari ‏@AVIVA1950  Mar 31

LIVE Price & Value, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00… @Pharma_BI @AVIVA1950 @MassBio #AM2016 #PATIENTDRIVEN

 

Aviva Lev-Ari ‏@AVIVA1950  Mar 31

LIVE @ Sonesta – 2016 MassBio 11:45AM – 1:30AM The MassBio Annual Award Lunchon via @Pharma_BI @AVIVA1950 #AM2016 @MassBio #PATIENTDRIVEN

 

Aviva Lev-Ari ‏@AVIVA1950  Mar 31

The Microbiome, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00… – @Pharma_BI #PATIENTDRIVEN

 

 

Aviva Lev-Ari ‏@AVIVA1950  Mar 31

3-Plenary Session: The Microbiome, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00… @Pharma_BI @MassBio #AM2016 @AVIVA1950

 

Aviva Lev-Ari ‏@AVIVA1950  Mar 31

LIVE @ Sonesta — Welcome Remarks & Keynote – Kate Marshall @MassBio – Annual Meeting 0… http://pharmaceuticalintelligence.com/2016/03/31/2016@Pharma_BI … @MassBio #AM2016 @AVIVA1950

 

  1. Aviva Lev-Ari‏@AVIVA1950 Mar 30

I will Tweet in Real Time Tomorrow and Friday @pharma_BI and @AVIVA1950 @MassBio #AM2016 http://pharmaceuticalintelligence.com 

 

  1. Aviva Lev-Ari‏@AVIVA1950 Mar 30

Tomorrow I am @MassBio & will use the hashtag #AM2016 by @AVIVA1950 by @Pharma_BI

 

Read Full Post »

Real Time Coverage and eProceedings of The 2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

Curator: Aviva Lev-Ari, PhD, RN

 

2016 MassBio LIVE @ Sonesta — Welcome Remarks & Keynote – Kate Marshall @MassBio – Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA 3/31, 9AM – 10:15AM

http://pharmaceuticalintelligence.com/2016/03/31/2016-massbio-live-sonesta-welcome-remarks-keynote-kate-marshall-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma-331-9am-10/

LIVE @ Sonesta – 2016 MassBio 11:45AM – 1:30AM The MassBio Annual Award Lunchon

http://pharmaceuticalintelligence.com/2016/03/31/live-sonesta-2016-massbio-1145am-130am-the-massbio-annual-award-lunchon/

5-Plenary Session: Price & Value, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

http://pharmaceuticalintelligence.com/2016/03/31/5-plenary-session-price-value-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma/

Plenary Session: Biosimilars, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

http://pharmaceuticalintelligence.com/2016/03/31/6-plenary-session-biosimilars-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma/

An Evolving Paradigm of Drug Discovery – Externalization, Virtualization, De-virtualization, Contract Research & Strategic Partnerships, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

http://pharmaceuticalintelligence.com/2016/03/31/an-evolving-paradigm-of-drug-discovery-externalization-virtualization-de-virtualization-contract-research-strategic-partnerships-2016-massbio-annual-meeting-03312016-800-am-0/

Plenary Session: Immunotherapy in Combination, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

http://pharmaceuticalintelligence.com/2016/04/01/plenary-session-immunotherapy-in-combination-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma/

Plenary Session: Innovative Pricing Pricing Models: The Future is Now, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

http://pharmaceuticalintelligence.com/2016/04/01/plenary-session-innovative-pricing-pricing-models-the-future-is-now-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma/

LIVE @ Congressman Richard Neal – D-MA, Dean of MA Delegation 2016 MassBio Annual Meeting 04/01/2016 11AM Royal Sonesta Hotel, Cambridge, MA

http://pharmaceuticalintelligence.com/2016/04/01/live-congressman-richard-neal-d-ma-dean-of-ma-delegation-2016-massbio-annual-meeting-04012016-11am-royal-sonesta-hotel-cambridge-ma/

Plenary Session: The 2016 National Landscape, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA – 4/1 @11AM

http://pharmaceuticalintelligence.com/2016/04/01/plenary-session-the-2016-national-landscape-2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-hotel-cambridge-ma-41-11am/

LIVE Remarks by Rachel Kaprielian, Tony Chat and Mike Huckman @ 2016 MassBio Annual Meeting 04/01/2016 12:45 PM Royal Sonesta Hotel, Cambridge, MA

http://pharmaceuticalintelligence.com/2016/04/01/live-remarks-by-rachel-kaprielian-tony-chat-and-mike-huckman-2016-massbio-annual-meeting-04012016-1245-pm-royal-sonesta-hotel-cambridge-ma/

 

Read Full Post »

« Newer Posts - Older Posts »